RSS Johnson & Johnson's RYBREVANT Plus Chemotherapy Approved In Canada For Advanced Lung Cancer

[Crax Bot]

Johnson & Johnson (JNJ) has reported that Health Canada granted a Notice of Compliance for RYBREVANT (amivantamab for injection) in combination with carboplatin and pemetrexed, a form of platinum-based chemotherapy. This approval is for treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by activating epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, particularly in those whose condition has worsened following treatment with osimertinib.

The approval from Health Canada is supported by outcomes from the Phase 3 randomized, open-label, multicentre MARIPOSA-2 study. Findings from this study indicated that the addition of RYBREVANT to carboplatin and pemetrexed markedly enhanced progression-free survival compared to the use of carboplatin and pemetrexed alone.

The material has been provided by InstaForex Company - www.instaforex.com

Click to read more...